blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3510036

EP3510036 - IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.05.2022
Database last updated on 14.11.2024
FormerThe patent has been granted
Status updated on  18.06.2021
FormerGrant of patent is intended
Status updated on  24.02.2021
FormerExamination is in progress
Status updated on  14.04.2020
FormerRequest for examination was made
Status updated on  14.06.2019
FormerThe international publication has been made
Status updated on  23.03.2018
Formerunknown
Status updated on  29.09.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
GlaxoSmithKline Biologicals SA
Rue de l'Institut, 89
1330 Rixensart / BE
[2021/29]
Former [2019/29]For all designated states
GlaxoSmithKline Biologicals S.A.
Rue de l'Institut, 89
1330 Rixensart / BE
Inventor(s)01 / BAZIN-LEE, Helene G
c/o GlaxoSmithKline
553 Old Corvallis Road
Hamilton Montana 59840-3607 / US
02 / BURKHART, David
c/o GlaxoSmithKline
553 Old Corvallis Road
Hamilton Montana 59840-3607 / US
03 / COCHRAN, Michael
c/o GlaxoSmithKline
553 Old Corvallis Road
Hamilton Montana 59840-3607 / US
04 / EVANS, Jay T
c/o GlaxoSmithKline
553 Old Corvallis Road
Hamilton Montana 59840-3607 / US
05 / JOHNSON, David A
c/o GlaxoSmithKline
553 Old Corvallis Road
Hamilton Montana 59840-3607 / US
 [2019/29]
Representative(s)Furstoss, Olivia Aline
GSK
W23-F3
20, avenue Fleming
1300 Wavre / BE
[N/P]
Former [2019/29]Furstoss, Olivia Aline
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex, TW8 9GS / GB
Application number, filing date17768708.405.09.2017
[2019/29]
WO2017EP72152
Priority number, dateUS201662384618P07.09.2016         Original published format: US 201662384618 P
[2019/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018046460
Date:15.03.2018
Language:EN
[2018/11]
Type: A1 Application with search report 
No.:EP3510036
Date:17.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 15.03.2018 takes the place of the publication of the European patent application.
[2019/29]
Type: B1 Patent specification 
No.:EP3510036
Date:21.07.2021
Language:EN
[2021/29]
Search report(s)International search report - published on:EP15.03.2018
ClassificationIPC:C07D487/14, A61K31/4745, C07F9/6561, A61P37/04
[2019/29]
CPC:
C07F9/6561 (EP,US); A61K31/4745 (EP); A61P37/04 (EP);
C07D471/04 (US); C07D487/14 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/29]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:IMIDAZOCHINOLINDERIVATE UND DEREN VERWENDUNG IN DER THERAPIE[2019/29]
English:IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY[2019/29]
French:DÉRIVÉS D'IMIDAZOQUINOLINE ET LEUR UTILISATION EN THÉRAPIE[2019/29]
Entry into regional phase26.03.2019National basic fee paid 
26.03.2019Designation fee(s) paid 
26.03.2019Examination fee paid 
Examination procedure26.03.2019Examination requested  [2019/29]
26.03.2019Date on which the examining division has become responsible
15.10.2019Amendment by applicant (claims and/or description)
17.04.2020Despatch of a communication from the examining division (Time limit: M06)
09.10.2020Reply to a communication from the examining division
25.02.2021Communication of intention to grant the patent
11.06.2021Fee for grant paid
11.06.2021Fee for publishing/printing paid
11.06.2021Receipt of the translation of the claim(s)
Opposition(s)22.04.2022No opposition filed within time limit [2022/26]
Fees paidRenewal fee
11.09.2019Renewal fee patent year 03
11.09.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.09.2017
AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
MK21.07.2021
MT21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
LU05.09.2021
CH30.09.2021
LI30.09.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
[2024/42]
Former [2024/23]HU05.09.2017
AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
MK21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
LU05.09.2021
CH30.09.2021
LI30.09.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2023/33]HU05.09.2017
AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
LU05.09.2021
CH30.09.2021
LI30.09.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2023/30]AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
LU05.09.2021
CH30.09.2021
LI30.09.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/37]AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
LU05.09.2021
CH30.09.2021
LI30.09.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/34]AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
LU05.09.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/29]AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/25]AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/24]AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SK21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/21]AT21.07.2021
DK21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
PL21.07.2021
RS21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/11]AT21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
PL21.07.2021
RS21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/09]AT21.07.2021
FI21.07.2021
LT21.07.2021
RS21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
PT22.11.2021
Former [2022/08]AT21.07.2021
FI21.07.2021
LT21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
Former [2022/07]AT21.07.2021
LT21.07.2021
NO21.10.2021
Cited inInternational search[X]WO2005020999  (3M INNOVATIVE PROPERTIES CO [US], et al) [X] 30* page 188; example 119 *;
 [X]WO2007100634  (3M INNOVATIVE PROPERTIES CO [US], et al) [X] 30 * pages 63-65; compound 9 and intermedaite used in its preparation *;
 [ID]WO2010048520  (GLAXOSMITHKLINE BIOLOG SA [BE], et al) [ID] 1-39 * claims 1-3 *;
 [XA]WO2012031140  (NOVARTIS AG [CH], et al) [X] 30 * claim 14 * * page 59; compound 35 * [A] 1-29,31-39;
 [AP]WO2017102654  (GLAXOSMITHKLINE BIOLOGICALS SA [BE]) [AP] 1-39 * the whole document *;
 [AP]WO2017102652  (GLAXOSMITHKLINE BIOLOGICALS SA [BE]) [AP] 1-39 * the whole document *
by applicantWO2005020999
 US8624029
    - IWASAKI, A., Nat Immunol, (20040000), vol. 5, page 987
    - AKIRA, S., Nat Rev Immunol, (20040000), vol. 4, page 499
    - TAKEDA, K., Semin Immunol, (20040000), vol. 16, page 3
    - ZUGHAIER, S., Infect Immun, (20050000), vol. 73, page 2940
    - HEIL, F., Eur J Immunol, (20030000), vol. 33, page 2987
    - GORDON, J Immunol, (20050000), page 1259
    - ROSEMEYER, H., Chemistry & Biodiversity, (20050000), vol. 2, pages 977 - 1063
    - GERSTER et al., J. Med. Chem., (20050000), vol. 48, page 3481
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.